Comment Not Generic YET (Score 4, Informative) 491
Lipitor has had an ANDA filed for a generic version by Watson, yes. However, the law allows Pfizer to grant a 180 day exclusivity contract to a manufacturer of their choice (in this case Watson) for the ANDA. To those affected by this drug going generic: IT HAS NOT GONE TRULY GENERIC YET! Wait until the 180 day exclusivity contract expires (in 179 days) and the true "invisible hand" will take effect in the market.
In the meantime, you're most likely going to need to get the BRAND NAME Lipitor for it to be covered to the fullest extent by your pharmacy benefit manager ("insurance company")! These PBMs get rebates (NOT kickbacks) to lower the cost of the brand-name drug, so it's financially advantageous to the member to not cover the generic yet. Here's why:
Lipitor (brand) 90ct bottle = $550 retail, minus $330 in rebates = $220 total cost of drug.
atorvastatin by Watson (generic) 90ct bottle = $530 retail, minus $0 in rebates (Watson doesn't offer any) = $550 total cost of drug.
(These amounts are fictional, however they represent true real-world scenarios.)
Disclaimer: I work for one of the US' largest Pharmacy Benefit Managers in the Clinical Review department. We had a meeting today regarding all of our Medicare Part-D patients and how they're affected by this specific drug going generic. No suits were involved and the members are receiving the best possible drug savings until the exclusivity contract expires. Once it expires the new generics will be placed on the tier-1 ("generic") copay structure.